Anoro Ellipta is a brand-name prescription medication to manage chronic obstructive pulmonary disease (COPD) symptoms in adults. Common side effects of Anoro Ellipta are generally mild, but serious ...
RESEARCH TRIANGLE PARK, NC and SOUTH SAN FRANCISCO, CA--(Marketwired - Apr 28, 2014) - GlaxoSmithKline plc (LSE: GSK) (NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that Anoro™ ...
ANORO™ ELLIPTA™ approved as first once-daily dual bronchodilator for the treatment of COPD in the US
GlaxoSmithKline plc (LSE/NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the US Food and Drug Administration (FDA) has approved ANORO™ ELLIPTA ...
Anoro Ellipta (umeclidinium/vilanterol) is a prescription drug that’s used to treat chronic obstructive pulmonary disease (COPD). Anoro Ellipta’s cost may depend ...
Anoro Ellipta is a brand-name inhaler that’s prescribed for long-term chronic obstructive pulmonary disease (COPD) treatment. Anoro Ellipta contains the active ingredients vilanterol and umeclidinium.
LONDON, UNITED KINGDOM and SOUTH SAN FRANCISCO, CA--(Marketwired - Oct 17, 2014) - Theravance, Inc. (NASDAQ: THRX) -- Respiratory Medicine has published positive results from a third lung function ...
The U.S. Food and Drug Administration have approved GlaxoSmithKline’s Anoro™ Ellipta™, the company announced. The product is used to treat chronic obstructive ...
Anoro Ellipta (umeclidinium and vilanterol inhalation powder) is a combination of two bronchodilators in a single dry powder inhaler, the Ellipta. It contains umeclidinium (UMEC), a long-acting ...
RESEARCH TRIANGLE PARK, N.C. and SOUTH SAN FRANCISCO, Calif., April 28, 2014 /PRNewswire/ -- GlaxoSmithKline plc (LSE/NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that Anoro™ Ellipta ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback